Emerald Health Therapeutics, Inc.

Reported Q2 net revenue was $3 million, up $0.8 million from the previous quarter, and gross revenue increased 42% sequentially to $3.8 million. Revenue mix shifted to 70% dried cannabis flower and 30% concentrates, extracts and edibles, versus 61% and 39% in the prior quarter. Total cost of sales exceeded total revenues by $0.3 million, improving by $0.7 million sequentially, but the company still recorded a small negative gross margin. SG&A totaled $4.1 million, up $0.6 million, and net loss was $14 million, including $10.7 million of asset impairment. Net working capital was $32.3 million, including $26.9 million of cash and no significant debt. Cash used in operating activities was $3.4 million versus $4.9 million in the prior quarter. Management did not provide formal next-quarter or full-year financial guidance, but said it expects to continue increasing sales and marketing investment, progress partnered clinical trials in early Q4, and potentially strengthen cash through divestment of non-strategic assets.

Riaz Bandali framed Q2 as evidence that the company’s renewed strategy is starting to work, while cautioning that the turnaround will not be linear and there may be “bumpy quarters” ahead. He emphasized science-based innovation, Emerald Defined Dose, and new product launches like FUSE, Nano Shots, and sublingual tablets, saying initial consumer response has been encouraging. He also highlighted strategic partnerships, Quebec production investments, and a more disciplined, cleaner balance sheet as central to the company’s path forward.

Jenn Hepburn emphasized that the quarter improved operationally, with net revenue of $3 million, SG&A of $4.1 million, and operating cash use down to $3.4 million from $4.9 million in the prior quarter. She noted the company’s $32.3 million of net working capital, including $26.9 million in cash and no significant debt, and pointed to the voluntary move from the TSXV to the CSE as a way to lower compliance costs and improve flexibility. She also explained that the $14 million net loss was heavily affected by a $10.7 million impairment on held-for-sale assets, mainly the Metro Vancouver facility.

There was no formal analyst Q&A segment in the transcript. Management instead proactively addressed common investor concerns: near-term margin pressure, the impact of asset write-downs, cash usage, and how the company plans to fund growth. They said the balance sheet is strong enough to support the strategy and that non-strategic asset sales could further strengthen cash in the next few quarters.